- Home
- COLL vs SUPV Comparison
COLL vs SUPV Comparison
Compare COLL & SUPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- SUPV
- Stock Information
- Founded
- COLL 2002
- SUPV 1887
- Country
- COLL United States
- SUPV Argentina
- Employees
- COLL N/A
- SUPV N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- SUPV Commercial Banks
- Sector
- COLL Health Care
- SUPV Finance
- Exchange
- COLL Nasdaq
- SUPV Nasdaq
- Market Cap
- COLL 1.1B
- SUPV 908.5M
- IPO Year
- COLL 2015
- SUPV 2016
- Fundamental
- Price
- COLL $33.35
- SUPV $16.83
- Analyst Decision
- COLL Strong Buy
- SUPV Buy
- Analyst Count
- COLL 5
- SUPV 2
- Target Price
- COLL $43.80
- SUPV $17.00
- AVG Volume (30 Days)
- COLL 486.5K
- SUPV 1.5M
- Earning Date
- COLL 02-20-2025
- SUPV 03-10-2025
- Dividend Yield
- COLL N/A
- SUPV 1.01%
- EPS Growth
- COLL 757.11
- SUPV 67.85
- EPS
- COLL 2.16
- SUPV 0.19
- Revenue
- COLL $599,245,000.00
- SUPV $435,663,160.00
- Revenue This Year
- COLL $13.20
- SUPV N/A
- Revenue Next Year
- COLL $17.63
- SUPV N/A
- P/E Ratio
- COLL $15.42
- SUPV $19.60
- Revenue Growth
- COLL 9.62
- SUPV N/A
- 52 Week Low
- COLL $28.39
- SUPV $3.71
- 52 Week High
- COLL $42.29
- SUPV $19.75
- Technical
- Relative Strength Index (RSI)
- COLL 62.31
- SUPV 54.80
- Support Level
- COLL $32.29
- SUPV $17.36
- Resistance Level
- COLL $33.99
- SUPV $19.75
- Average True Range (ATR)
- COLL 1.29
- SUPV 1.19
- MACD
- COLL 0.51
- SUPV -0.13
- Stochastic Oscillator
- COLL 87.40
- SUPV 40.48
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, Asset Management, and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.